We have investigated the effect of nicotinic receptor ligands in the behavioral sensitization (hyperlocomotion) and rewarding properties (conditioned place preference paradigm, CPP) of 3,4-methylenedioxy-methamphetamine (MDMA) in mice. Each animal received intraperitoneal pretreatment with either saline, dihydro-β-erythroidine (DHβE, 1 mg/kg) or varenicline (VAR, 0.3 mg/kg), 15 min prior to subcutaneous saline or MDMA (5 mg/kg), for 10 consecutive days. On day 1, both DHβE and VAR inhibited the MDMA-induced hyperlocomotion. After 10 days of treatment, MDMA induced a hyperlocomotion that was not reduced (rather enhanced) in antagonistpretreated animals. This early hyperlocomotion was accompanied by a significant increase in heteromeric nicotinic receptors in cortex that was not blocked by DHβE or VAR. Behavioral sensitization to MDMA was highest 2 weeks after the discontinuation of MDMA treatment. This additional increase in sensitivity was prevented in animals pretreated with DHβE or VAR. At this time, MDMA-treated mice showed a significant increase in heteromeric receptors in cortex that was prevented by DHβE and VAR. An involvement of α7 nicotinic receptors in this effect is ruled out. MDMA (10 mg/kg) induced positive CPP that was abolished by DHβE (2 mg/kg) and VAR (2 mg/kg). Moreover, chronic nicotine pretreatment (2 mg/kg, ip, b.i.d., for 14 days) caused MDMA, administered at a low dose (3 mg/kg), to induce CPP, which would otherwise not occur. Finally, present results point out that heteromeric nicotinic receptors are involved in locomotor sensitization and addictive potential induced by MDMA. Thus, varenicline might be a useful drug to treat both tobacco and MDMA abuse at once.
Introduction
MDMA is a synthetic drug that has properties of both stimulants and hallucinogens. Compared to other amphetamine derivatives, MDMA triggers a larger increase in serotonin and a smaller increase in dopamine release (Johnson et al., 1986) . The behavioral and neurochemical adaptations related to chronic MDMA treatment are largely unknown. For instance, an increase in the functionality of cortical 5-HT 2A and a decrease in striatal D 2 receptors in mice treated with MDMA have been described (Varela et al., 2011) . Many drugs of abuse, at low doses, can increase motor behavior producing heightened locomotion and exploration (Wise and Bozarth, 1987) and, after repeated administration, behavioral sensitization can arise from various neuroadaptations in multiple brain nuclei. This is not only the result of distinct molecular targets for the drugs, but may also include a differential involvement of learned associations. It is postulated that the relatively more robust pharmacological capacity of amphetamine derivatives to release dopamine may induce a form of sensitization that is more dependent on adaptations in mesoaccumbens dopamine transmission in comparison to cocaine and morphine sensitization (Vanderschuren and Kalivas, 2000) .
There is evidence that acetylcholine plays an important role in the hyperlocomotor activity induced by psychostimulants (Williams and Adinoff, 2008) . Dihydro-β-erythroidine (DHβE), a high-affinity competitive antagonist of α4 subunit-containing nAChR (nicotinic acetylcholine receptor) inhibits the induction of locomotor sensitization to d-amphetamine (Karler et al., 1996; Schoffelmeer et al., 2002) . Moreover, knockout mice lacking the β2 nAChR subunit do not selfadminister nicotine (Picciotto et al., 1999) and show less cocaineconditioned place preference than wild-type mice (Zachariou et al., 2001 ). All of these results indicate that heteromeric α4β2 nAChR subtypes appear to play an essential role in nicotine dependence (Govind et al., 2009) ; in this regard, an activation of α4β2 nAChR is strongly associated with dopamine release in the nucleus accumbens (NAcc) (Champtiaux et al., 2003) and with drug-seeking behavior (Balfour et al., 2000; Picciotto et al., 1999) . A particular feature of nAChR is Progress in Neuro-Psychopharmacology & Biological Psychiatry 44 (2013) 201-209 Abbreviations: AUC, area under the curve; CPP, conditioned place preference; DHβE, dihydro-β-erythroidine; MDMA, 3,4-methylenedioxy-methamphetamine; MLA, methyllycaconitine; NAcc, nucleus accumbens; nAChR, nicotinic acetylcholine receptors; VAR, varenicline; VTA, ventral tegmental area.
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